Immuneel Therapeutics and Arogya Finance have partnered to provide zero-cost EMIs up to Rs 25 lakh for advanced cancer treatments. The Saksham Patient Access Program aims to help families manage high upfront medical costs and prevent treatment delays.
Immuneel Therapeutics, a company focused on cell and gene therapy, has teamed up with the Mumbai-based non-banking financial company (NBFC) Arogya Finance to launch a new patient support initiative called the Saksham Patient Access Program. This partnership allows eligible patients seeking advanced cancer treatment to access financing of up to Rs 25 lakh through interest-free Equated Monthly Installments.
The program is designed to solve a specific problem in the healthcare sector where high upfront costs often act as a barrier to accessing cutting-edge therapies. By allowing patients to spread the cost of treatment over time, the initiative aims to prevent delays in critical medical care that could otherwise be caused by a lack of immediate liquidity.
How the Financing Model Works
Under the arrangement, the process begins with a medical screening conducted by Immuneel’s internal team to verify if the patient is a candidate for their specialized therapies. Once medical eligibility is established, patients are referred to a dedicated desk that handles the financial aspect. It is important to note that Arogya Finance will remain responsible for the independent assessment, approval, and management of these loan applications. This means that creditworthiness remains a factor, and not all patients who meet the medical criteria are guaranteed financial approval.
Context on Healthcare Financing
In India, the cost of specialized procedures like cell and gene therapy is often significantly higher than traditional treatment protocols. Companies in this space frequently face challenges regarding market penetration because of the high price point of these innovative therapies. Partnerships with specialized financial institutions like Arogya Finance are a strategy to expand the addressable patient base by lowering the barrier to entry.
For investors, these collaborations serve as a way to potentially support revenue sustainability for firms engaged in expensive biotech treatments. While this improves access, the actual success of such programs depends on the volume of patients who can pass the lender’s credit risk criteria. Since the financing is provided by a third-party NBFC, Immuneel avoids taking the direct credit risk on its own balance sheet, which is a positive factor for its financial stability.
Moving forward, the effectiveness of this program will be measured by the number of patients who successfully utilize the financing to complete their treatment cycles. Investors may track future updates from the company regarding patient enrollment rates and whether this model influences the overall uptake of its advanced therapy offerings.